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Platelet glycoprotein Ib (GpIb) mediates interaction
with both von Willebrand factor and thrombin. Throm-
bin binds to GpIb via its heparin-binding site (HBS) (De
Candia, E., De Cristofaro, R., De Marco, L., Mazzucato,
M., Picozzi, M., and Landolfi, R. (1997) Thromb. Haemo-
stasis 77, 735–740; De Cristofaro, R., De Candia, E.,
Croce, G., Morosetti, R., and Landolfi, R. (1998) Biochem.
J. 332, 643–650). To identify the thrombin-binding do-
main on GpIba, we examined the effect of GpIba1–282, a
GpIba fragment released by the cobra venom mocarha-
gin on the heparin-catalyzed rate of thrombin inhibition
by antithrombin III (AT). GpIba1–282 inhibited the reac-
tion in a dose-dependent and competitive fashion. In
contrast, the GpIba1–271 fragment, produced by exposing
GpIba1–282 to carboxypeptidase Y, had no effect on
thrombin inhibition by the heparin-AT complex. Meas-
urements of the apparent equilibrium constant of the
GpIba1–282 binding to thrombin as a function of different
salts (NaCl and tetramethyl-ammonium chloride) con-
centration (0.1–0.2 M) indicated a large salt dependence
(G6 5 24.5), similar to that pertaining to the heparin
binding to thrombin. The importance of thrombin HBS
in its interaction with GpIba was confirmed using DNA
aptamers, which specifically bind to either HBS (HD22)
or the fibrinogen recognition site of thrombin (HD1).
HD22, but not HD1, inhibited thrombin binding to
GpIba1–282. Furthermore, the proteolytic derivative gT-
thrombin, which lacks the fibrinogen recognition site,
binds to GpIba via its intact HBS in a reaction that is
inhibited by HD22. Neither a- nor gT-thrombin bound to
GpIba1–271, suggesting that the Asp
272–Glu282 region of
GpIba may act as a “heparin-like” ligand for the throm-
bin HBS, thereby inhibiting heparin binding to throm-
bin. It was also demonstrated that intact platelets may
dose-dependently inhibit the heparin-catalyzed throm-
bin inhibition by AT at enzyme concentrations <5 nM.
Altogether, these findings show that thrombin HBS
binds to the region of GpIba involving the Asp272–Glu282
segment, protecting the enzyme from the inactivation
by the heparin-AT system.
Platelet glycoprotein Ib (GpIb),1 which belongs to the so
called “leucine-rich repeat” family of proteins, binds to von
Willebrand factor, thus allowing the early adhesion of platelets
to exposed subendothelium (1, 2). In addition, GpIb also binds
to thrombin with high affinity (1). The inhibition of this inter-
action causes a reduced thrombin-induced platelet activation
through an unclear mechanism (3, 4).
GpIb is a 150-kDa transmembrane glycoprotein and contains
a 27-kDa b-subunit connected via a disulfide bond to the a-sub-
unit (5). Glycocalicin, the 140-kDa extracytoplasmic portion of
GpIba that bears the von Willebrand and thrombin-binding
sites can be prepared by hydrolyzing GpIba with endogenous
calcium-dependent sulfydryl proteases such as calpain (1).
Previous studies have shown that the GpIba thrombin-bind-
ing site maps to an extensive C-terminal region spanning res-
idues Cys209–Asp287 (6). Moreover, recent studies, indicate that
thrombin binds to GpIb via its heparin-binding site (HBS)
(7, 8).
In this study the structural mapping of GpIba domain that
interacts with the HBS on thrombin was further localized to
272–282 residues using GpIba1–282 and GpIba1–271, fragments
released from GpIba upon exposure to either mocarhagin, a
cobra venom extract (9), or mocarhagin plus carboxypeptidase
Y. To investigate the consequences of the interaction of throm-
bin with GpIb, we examined the effect of single-stranded DNA
oligonucleotides that bind either to the HBS or the fibrinogen
recognition site of thrombin on (a) the heparin-catalyzed rate of
thrombin inhibition by antithrombin III in the presence of
paraformaldehyde-treated platelets or the two GpIba frag-
ments and (b) thrombin-induced platelet aggregation.
EXPERIMENTAL PROCEDURES
Materials—Human a-thrombin was purified and characterized as
previously reported (10). High molecular weight heparin (lot HF2025;
molecular weight 5 16,000) was purchased from Enzyme Research
Laboratories Inc. (South Bend, IN). The molecular weight of this hep-
arin fraction was confirmed by subjecting the material to gel filtration
using a Bio-Silect SEC 250–5 column (Bio-Rad) fitted to a high per-
formance liquid chromatograph (Perkin-Elmer, series 10) and monitor-
ing the fractions at 205 nm. Purified heparin oligosaccharides of known
molecular weights were used to construct the reference curve. Heparin
with high affinity for antithrombin was isolated by affinity chromatog-
raphy using an antithrombin III column (11). Antithrombin III (lot
HATIII 540AL) purchased from Enzyme Research Labs migrated as a
single band on 4–20% SDS-PAGE gels with an apparent molecular mass
of 58 kDa. The antithrombin concentration was calculated spectrophoto-
metrically, using an extinction coefficient E280 (1%) 5 6.5 (12). The chromo-
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genic substrate HD-Phe-Pip-Arg-p-nitroanilide (S2238) was from Chro-
mogenix (Mo¨lndal, Sweden). Sodium acetate, C-terminal (55–65) sulfated,
and nonsulfated hirudin fragments (Ac-DFEEIPEEY(SO3H)LQ), dan-
syl-chloride, a dansyl-L-amino acids kit, ethylammonium chloride, lith-
ium carbonate, methanol, trifluoroacetic acid (spectrophotometric
grade), trypsin-immobilized agarose (tosylphenylalanyl chloromethyl
ketone-treated), and prostaglandin E1 were from Sigma. Carboxypep-
tidase Y (excision grade), immobilized on Sepharose CL-4B resin, was
purchased from Pierce. Mocarhagin, purified from cobra venom (9), was
kindly provided by Dr. Robert K. Andrews (Baker Medical Research
Institute, Prahran, Australia).
The two single-stranded DNA oligonucleotides (a) 59-AGTCCGTGG-
TAGGGCAGGTTGGGGTGACT-39, referred to as HD22, and (b) 59-
GGTTGGTGTGGTTGG-39, referred to as HD1, were synthesized by the
Institute for Molecular Biology and Biotechnology at McMaster Univer-
sity (Hamilton, ON, Canada).
Purification of GpIba1–282 Fragment—GpIba1–282 was prepared by
mocarhagin treatment of washed platelets using a fast protein liquid
chromatography method, as previously reported for glycocalicin purifi-
cation (7). Briefly, platelets from outdated platelet concentrates (50
units) were washed three times by centrifugation in 10 mM Hepes, 0.135
M NaCl, 3 mM KCl, 0.1% bovine serum albumin, 5 mM prostaglandin E1,
pH 7.4. After washing, platelet suspensions were treated with 10 mg/ml
mocarhagin for 60 min at 37 °C in the above buffer without bovine
serum albumin and containing 1 mM CaCl2. This treatment is reported
to cause selective cleavage of the amidic bond between Glu282 and
Asp283 of GpIba (9). At the end of incubation, the reaction was stopped
by addition of 2 mM EDTA, and platelets were precipitated by centri-
fuging at 800 3 g for 15 min. The supernatant was chromatographed on
a high load Q-Sepharose column (Amersham Pharmacia Biotech) con-
nected to a fast protein liquid chromatography apparatus, and GpIba1–
282 was isolated according to previously reported methods for glycocali-
cin purification, using a gradient of 0–0.6 M NaCl for 60 min (7, 8). The
peak eluted at 0.55 M NaCl was collected and further analyzed. SDS-
PAGE showed that the purified protein had an apparent molecular
mass of 40 kDa under both nonreducing and reducing conditions. Pu-
rified GpIba1–282 (5 mg) was electrophoresed on a 4–20% SDS-PAGE
gel, transferred to nitrocellulose, blotted, and incubated with 2 mg/ml
purified mouse MoAb SZ2 purchased from Immunotech (Instrumenta-
tion Laboratory, Milano, Italy). This monoclonal antibody recognizes a
region of the N-terminal GpIba domain and inhibits both von Will-
ebrand and thrombin binding to GpIba. The GpIba1–282 band was
detected with alkaline phosphatase-labeled goat anti-mouse IgG (Sig-
ma-Aldrich). GpIba1–282 concentration was determined spectrophoto-
metrically at 280 nm, using a molar extinction coefficient equal to 33390
(cm21), as predicted on the basis of the sequence (13), by the method of
Pace and co-workers (14).
Treatment of GpIba1–282 with Immobilized Carboxypeptidase Y—Pu-
rified GpIba1–282 (at concentrations ranging from 5 to 10 mM) in 0.5 ml
of 10 mM phosphate buffer, 0.15 M NaCl, pH 6.5, was incubated with 0.5
ml of immobilized carboxypeptidase Y (;6 units) at 37 °C with gentle
stirring. At intervals ranging from 10 to 240 min., 50 ml of supernatant
from perchlorate-treated samples (0.3 M) were removed and subjected to
amino acid analysis according to the method of Levina and Nazimov
(15). Briefly, the solution was dried in vacuo at 60 °C and evaporated to
dryness twice from 5 ml of water. After addition of 40 mM lithium
carbonate buffer, pH 9.5, and dansyl chloride (10-fold excess relative to
GpIba1–282) in acetonitrile (3 ml), the mixture was centrifuged at 1000 3
g for 2 min and kept in darkness for 35 min at 20 °C prior to adding 3
ml of 0.1% ethylammonium chloride. After drying at 60 °C, a mixture of
5.7 M HCl and trifluoroacetic acid (2:1 v/v, 6 ml) was added to the
precipitate, and the resulting solution was frozen. After drying twice
with methanol, the sample was dissolved in methanol (5–10 ml) and
injected onto a Brownlee (Santa Clara, CA) RP 300 octyl analytical
column (220 3 4.6 mm) connected to a guard column of the same resin.
Elution was carried out with the following eluants: (a) 0.1% trifluoro-
acetic acid in water and (b) water:acetonitrile (40:60 v/v) in 0.1% trif-
luoroacetic acid. The applied gradient was 0–99% B in 90 min and 99%
B for 5 min at a flow rate of 1 ml/min. In separate experiments, a
reference reverse phase high pressure liquid chromatography chromat-
ogram was obtained by using a standard mixture of dansylated amino
acids.
The fragment of GpIba1–282 remaining after a 240-min exposure to
carboxypeptidase Y (GpIba1–271 fragment) was gel filtered on a Bio-Rad
DG10 column and concentrated using an Amicon Centriprep 3 mem-
brane. Its concentration was determined at 280 nm using a molar
extinction coefficient equal to 28920 (cm21). SDS-PAGE showed that
GpIba1–271 did not undergo further intramolecular fragmentation by
carboxypeptidase Y.
Because a sulfated tyrosine was expected in the hydrolyzed solution,
a reference chromatogram of carboxypeptidase Y-treated (4 h) sulfated
and nonsulfated C-terminal hirudin peptide 55–65 (Ac-DFEEIPEEY-
(SO3H)LQ) also was obtained. The assignment of the chromatographic
peak representing O-sulfated L-tyrosine was based on the known amino
acid composition of the peptide and the difference in the chromato-
graphic pattern obtained with the sulfated and nonsulfated peptide.
Inactivation of a-Thrombin by Antithrombin III in the Presence and
Absence of Heparin and GpIba1–282 Fragment—Previous studies indi-
cated that thrombin interaction with antithrombin (AT) occurs via the
following two-step reaction (16, 17).
T 1 AT^ T z AT 3 T-AT (Eq. 1)
where T is thrombin, TzAT is the reversible thrombin-antithrombin
adduct and T-AT is the final complex between enzyme and inhibitor.
Heparin accelerates the second step of the reaction by binding to both
thrombin and AT (17). Thus, the final T-AT adduct occurs through
formation of an intermediary ternary thrombin-heparin-AT complex,
which rearranges as follows.
T 1 AT z H-|0
KTzATH
T z AT z HO¡
kTzATH
T-AT 1 H (Eq. 2)
where ATzH is the reversible antithrombin-heparin complex, TzATzH is
the ternary intermediary thrombin-antithrombin-heparin adduct,
KTzATH is the equilibrium dissociation constant for thrombin binding to
the heparin-antithrombin complex, and kTzATH is the rate constant for
the conversion of the intermediary complex to the final T-AT adduct.
The heparin-catalyzed thrombin-AT interaction can be kinetically
analyzed using a formula describing a rapid equilibrium two-substrate
enzyme reaction, in which both thrombin and AT are the substrates and
heparin is the “enzyme” (17). Under experimental conditions where the
thrombin concentration is less than Km value for the heparin-thrombin
interaction and the AT concentration is more than the value for throm-
bin, one can assume that the inhibitor concentration does not change
during the inhibition reaction. This simplifies the mathematical treat-
ment of a two-substrate Michaelis equation, and the rate of thrombin
inactivation is well described by the following differential equation.
2dT
dt
5
kcat
KTzATH
H0
AT0
KATH 1 AT0
T 1 kuncatAT0T (Eq. 3)
where T is thrombin, AT0 is the AT concentration, H0 is the heparin
concentration, the ratio kcat/KTzATH is the specificity constant for throm-
bin interaction with heparin under saturating AT concentration, KATH
is the equilibrium dissociation constant for AT-heparin interaction, and
kuncat is the second order rate constant for the uncatalyzed thrombin-AT
reaction.
Integration of Equation 3 results in the following.
Tt 5 T0 exp ~2kobst! (Eq. 4)
where T0 and Tt are the thrombin concentrations at time 5 0 and
time 5 t, respectively. On the basis of Equations 3 and 4 we obtained
the following.
kobs 5
kcat
KTzATH
H0
AT0
KATH 1 AT0
1 kuncatAT0 (Eq. 5)
Equation 5 shows that thrombin inactivation is described by a pseudo-
first order exponential decay, characterized by a rate constant (kobs)
that is linearly correlated with the heparin concentration and hyper-
bolically plus linearly linked to AT concentration. Thus, the kcat/KTATH
value can be calculated from the AT dependence of the kobs values, once
the KATH value is known.
In our experimental set-up, kobs was measured by studying inactiva-
tion of 1 nM a-thrombin, in the presence of 4 nM heparin, as a function
of AT concentration (5–250 nM) in a final volume of 50 ml of 10 mM
Tris-HCl, 0.1–0.5 M NaCl, 0.1% PEG 6000, pH 7.50, at 25 °C. Thrombin
inhibition by AT was also studied as a function of GpIba1–282 and
GpIba1–271 (0–400 nM). At each AT concentration, the reaction was
quenched at various intervals by addition of 2 ml of 100 mM Phe-Pip-
Arg-pNA in 50 mM Tris-HCl, 0.1 M NaCl, 0.1% PEG 6000, pH 8.00. The
kobs value was then calculated using Equation 4.
Because the relationship between the observed KTzATH/kcat values
and GpIba1–282 concentration was linear, a competitive scheme was
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applied whereby GpIba1–282 binding to thrombin inhibited the binding
of heparin to thrombin and vice versa. According to this competitive
scheme, only the KTzATH value is expected to increase as a function of the
GpIba fragment. The experimental values of KTzATH/kcat (i.e. (KTzATH/
kcat)
obs) were thus fitted to the following relation.
SKTzATHkcat D
obs
5 SKTzATHkcat D
oS1 1 PKiD (Eq. 6)
where P is the concentration of GpIba1–282, Ki is the equilibrium binding
constant of GpIba1–282 for thrombin, and (KTzATH/kcat)° is the value of
KTzATH/kcat for thrombin interaction with the AT-heparin complex in the
absence of the GpIba1–282 fragment.
Thrombin inhibition by AT in the absence of heparin was studied
using the following reaction scheme for irreversible inhibition (17).
T 1 S-|0
Km
TSO¡
kcat
T 1 P (Eq. 7)
1
AT
2 k
T-AT
where k is the rate constant for irreversible thrombin inhibition. Ex-
periments were performed by using the Phe-Pip-Arg-pNA substrate
and a-thrombin at concentrations of 200 mM and 0.5–3 nM, respectively.
Antithrombin was typically used at a concentration of 2.5 mM. The
buffer used for these kinetic experiments was 10 mM Hepes, 0.15 M
NaCl, 0.1% PEG 6000, pH 7.50, at 25 °C. The concentration of pNA
released from the substrate was followed at 405 nm, and the experi-
mental points were fitted to the following equation (17).
@pNA#t 5 @pNA#inf@1 2 exp~kt!# (Eq. 8)
where [pNA]t and [pNA]inf are the pNA concentration at time 5 t and
time 5 infinity, respectively, and k is the pseudo-first rate constant for
the irreversible thrombin inhibition. The analysis of these data, along
with those pertaining to the experiments described above, was per-
formed using GRAFIT software (Erithacus Software Ltd., Staines, UK)
based on a modified Marquardt algorithm.
Preparation of gT-Thrombin—The proteolytic form of thrombin, re-
ferred to as gT-thrombin, was produced using immobilized trypsin, as
described previously (18). When subjected to SDS-PAGE under reduc-
ing conditions, the purified material showed two bands with a molecu-
lar mass of about 26 and 14 kDa, respectively. Purified gT-thrombin was
100% active, as determined by active site titration with p-nitrophenyl-
guanidinobenzoate. This thrombin derivative did not clot fibrinogen but
was readily inhibited by AT in the presence of heparin, as shown using
the assay procedure reported above. Typically, 1 nM gT-thrombin, 150
nM AT, and 4 nM heparin were used in these inhibition experiments.
Effect of Salt and the Single-stranded DNA Oligonucleotides HD22
and HD1 on Thrombin-GpIba1–282 Interaction—The effect of salt and
both HD22 and HD1 on the thrombin-GpIba 1–282 fragment interac-
tion was studied using a solid phase binding assay. The GpIba1–282
fragment was absorbed to the wells of a Dynatech Immulon microplate
by incubating 1 mg/ml GpIb fragment in 0.1 M carbonate buffer, pH 9.60,
overnight at 4 °C. The salt dependence of the Kd binding of GpIba1–282
to thrombin was investigated in the salt concentration range from 0.1 to
0.2 M, when NaCl or tetramethylammonium chloride (TMACl) were
used, or at 0.2 M, when NaF was used. Human a-thrombin was used
over a range of 5–2500 nM.
In the experiments using HD1 and HD22, these oligonucleotides
were both used over a concentration range of 0–200 nM. When gT-
thrombin was used, its concentration ranged from 7.8 nM to 1 mM, and
HD22 was used at 1 mM.
A progressive increase in the apparent Kd for a-thrombin-GpIb frag-
ment was observed upon HD22 addition. Based on this finding, we
analyzed the experimental data by applying a competitive inhibition
scheme whereby HD22 competitively inhibits thrombin binding to the
immobilized GpIba fragment and vice versa. Such a scheme was previ-
ously used to analyze the heparin effect on the thrombin-glycocalicin
interaction (8). However, because of its high affinity for thrombin (19),
the concentration of free HD22 changes upon binding to thrombin. In
this experimental set up, the two interacting macromolecules (thrombin
and HD22) were present in comparable amounts. This forced us to use
appropriate equations cast in terms of the total, rather than the free,
HD22 concentration (20, 21). The latter, Hf, is determined as follows.
Hf 5 ~Ht 2 et 2 Ki 1 Q!/2 (Eq. 9)
Q 2 ~˛Ht 2 et 2 Ki!2 1 4K1Ht (Eq. 10)
where Ht is the total HD22 concentration, et is the total thrombin
concentration, and Ki is the equilibrium dissociation constant for
thrombin-HD22 interaction. The concentration of bound HD22, Hb, is
determined as follows.
Hb 5 Ht 2 Hf (Eq. 11)
From a conservation relationship, it is known that the concentration of
thrombin bound to HD22, eb, equals the concentration of bound HD22,
Hb. Hence
ef 5 ct 2 Hb (Eq. 12)
Because of the competitive effect of HD22 on the thrombin-GpIba
interaction, the concentration of thrombin bound to the immobilized
GpIba fragment, e 2 GpIb, was calculated using the following relation.
e 2 GpIb 5 ~e 2 GpIb)max cf/~ef 1 Kd! (Eq. 13)
where (e 2 GpIb)max is the maximum value of e 2 GpIb complex, and
Kd* (the apparent equilibrium dissociation constant for thrombin-
GpIba interaction in the presence of a given HD22 concentration) is
defined by the following equation.
Kd* 5 Kdo~1 1 Hf/Ki! (Eq. 14)
where Kd° is the true equilibrium dissociation constant for the throm-
bin-GpIba interaction and Ki is the HD22-thrombin binding constant.
Experimental points pertaining to the HD22 effect on thrombin-
GpIba were simultaneously fitted to Equations 9–14 to enhance the
degrees of freedom in the fitting procedure and provide more robust
results (8).
Effect of Intact Platelets on the Heparin-catalyzed Inhibition of
Thrombin by Antithrombin III—Platelets, gel filtered as described pre-
viously (18), were suspended in 10 mM Hepes, 0.135 M NaCl, 5 mM KCl,
5.5 mM glucose, 2 mM CaCl2, pH 7.4. The platelet suspension (200,000/
ml) was divided in two aliquots: one was used as control, and the other
one was subjected to mocarhagin treatment (10 mg/ml) at 37 °C for 20
min. At the end of incubation, platelets were centrifuged at 2000 3 g for
10 min and washed three times in 10 mM Hepes, 0.15 M NaCl, 0.1% PEG
6000, 10 mM prostaglandin E1, pH 7.40. The final platelet suspensions
were treated with 0.4% (final concentration) formaldheyde at 25 °C for
1 h and washed three times in the above buffer. With cytofluorimetric
analysis (Becton Dickinson FACScan instrument) using fluorescein
isothiocyanate-coupled anti-GpIba MoAb SZ2, mocarhagin-treated
platelets demonstrated minimal labeling compared with control (see
below).
The effect of formaldehyde-treated intact or mocarhagin-exposed
platelets on the heparin-catalyzed rate of thrombin inhibition by AT
was assessed by incubating 0.5–5 nM thrombin at 25 °C with varying
concentrations of platelets (30,000–200,000/ml), 15 nM heparin, 0.25 mM
AT, and 70 mM of the chromogenic substrate Phe-Pip-Arg-pNA in 10 mM
Hepes, 0.15 M NaCl, 0.1% PEG 6000, pH 7.50. At intervals, the reaction
was stopped by adding 100 nM hirudin, and after precipitating the
platelets by centrifugation at 6000 rpm for 5 min, the p-nitroaniline in
the supernatant was measured at 405 nm. An apparent pseudo-first
order rate constant for thrombin inhibition was calculated using
GRAFIT software.
Effect of HD1 and HD22 on Thrombin-induced Platelet Aggrega-
tion—Platelets, gel filtered as described previously (18), were sus-
pended in 20 mM Hepes, 0.135 M NaCl, 5 mM KCl, 0.2% bovine serum
albumin, 5.5 mM glucose, 2 mM CaCl2, pH 7.4. Platelet aggregation in
response to 1 nM thrombin was studied using a dual channel aggre-
gometer according to the Born method, in the absence or presence of
HD22 or HD1 in concentrations ranging from 1.5 to 400 nM and from 1.5
to 90 nM, respectively. The maximum velocity of absorbance change was
measured and expressed as a percentage relative to a control measured
in the absence of effector.
Effect of HD22 on Thrombin-induced Calcium Mobilization in Intact
and GpIb-depleted Platelets—Intraplatelet calcium mobilization in-
duced by thrombin was evaluated using the fluorescent dye for Ca21,
Fura 2-acetoxymethyl ester, as described previously (18). Fura 2-loaded
gel filtered platelets were divided into two aliquots, one of which was
subjected to mocarhagin treatment, while the other served as a control.
Platelet suspensions were incubated in the presence of 1 mM CaCl2 at
37 °C for 30 min with either 10 mg/ml mocarhagin or buffer alone. At the
end of incubation, 2 mM EDTA was added to quench the mocarhagin
activity. Intact or mocarhagin-treated platelets were then stimulated
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with 1 nM a-thrombin in the presence of 25, 100, and 400 nM HD22
aptamer, and the lag time for calcium increase was the parameter used
to evaluate the kinetics of calcium increase under the various experi-
mental conditions, as previously detailed (18, 22).
RESULTS
Purification of GpIba1–282 and of GpIba1–271—Mocarhagin
treatment of platelets releases a component with a molecular
mass of 40 kDa. This purified protein was recognized by a
monoclonal antibody, SZ2, directed against the sulfated tyro-
sine sequence of GpIba (Fig. 1). In contrast, this monoclonal
antibody did not recognize the GpIba1–271, the fragment ob-
tained after 240 min of carboxypeptidase treatment (Fig. 1).
After 240-min incubation with immobilized carboxypeptidase
Y, the amino acids released from GpIba1–282 were one threo-
nine, one leucine, one proline, two glutamic acid residues, three
aspartic acid residues, 2.6 sulfated tyrosine residues, and 0.4
tyrosine residues. This amino acid composition corresponds to
the sequence (NH2)DTDLY(S03)DY(S03)Y(S03)PEE(COOH),
which is the Asp272–Glu282 region of GpIba. The presence of
;2.6 sulfated tyrosines in the hydrolyzed amino acid mixture is
in agreement with previous results suggesting that about 50%
of Tyr276 is sulfated (9). Although definitive confirmation of the
sulfation status of Tyr276 is beyond the scope of the present
study, it is noteworthy that the peak reflecting the authentic
tyrosine (at 41.7 min) was the last to appear during the course
of the hydrolysis reaction (data not shown). This suggests that
Tyr276 may undergo only partial post-translational sulfation.
Effect of Single-stranded DNA Oligonucleotides on a-Throm-
bin Interaction with GpIba1–282 and GpIba1–271—The effect of
HD1 and HD22 on thrombin interaction with immobilized
GpIba1–282 and GpIba1–271 was evaluated. HD22 is known to
bind with high affinity to thrombin HBS (19). Furthermore,
HD22 did not bind to a thrombin variant with mutations in the
HBS (Arg93 3 Ala, Arg97 3 Ala, and Arg101 3 Ala; data not
shown). These findings confirm the specificity of HD22 for the
HBS of thrombin. This aptamer competed with thrombin for
GpIba1–282 binding (Fig. 2). Using Equations 9–14 to analyze
the data, HD22 binds to a-thrombin with a Kd value of 24 6 5
nM. This value was in good agreement with the Kd value of 26
nM, determined either by measuring the binding of the aptamer
to fluorescently labeled thrombin or the binding of fluorescent
aptamer to unlabeled thrombin (data not shown). The Kd value
for the thrombin-GpIba1–282 interaction was 149 6 15 nM, in
good agreement with the Kd value of 188 6 35 nM derived from
functional experiments examining the effect of the GpIba1–282
fragment on heparin-catalyzed thrombin inhibition by AT, as
detailed below.
In contrast, HD1 did not affect a-thrombin binding to
GpIba1–282, as shown in Fig. 3. Based on the demonstrated
specificity of HD1 interaction with the fibrinogen recognition
site on thrombin (23–25), these results rule out a significant
contribution of the fibrinogen recognition site to thrombin in-
teraction with GpIba1–282. Using the same solid phase binding
assay, immobilized GpIba1–271 did not bind thrombin (Fig. 3),
findings consistent with the results obtained in the functional
experiments, which demonstrated no effect of the GpIba1–271
fragment on the heparin-catalyzed rate of thrombin inhibition
by AT (see below). Altogether, these experiments suggest that
the region 272–282 of GpIba is important in driving the ener-
getics of thrombin interaction.
Interaction of gT-Thrombin with GpIba1–282—The interac-
tion of gT-thrombin with immobilized GpIba1–282 is character-
ized by a Kd value of 281 nM, which is ;85% higher than that
of a-thrombin (Fig. 4). Thus, even though gT-thrombin has an
impaired fibrinogen recognition site, it still binds to GpIba,
presumably via its HBS, which is intact (26). HD22 can dis-
place gT-thrombin from immobilized GpIba, as shown in Fig. 4.
It is noteworthy that in separate experiments HD22 has been
shown to bind to g-thrombin with a Kd value of about 15 nM
(data not shown).
Effect of Salt on Thrombin Interaction with the GpIba1–282
Fragment—Measurement of the apparent equilibrium con-
stant of GpIba1–282 fragment binding to a-thrombin, as de-
tailed above, under different salt concentration permits analy-
sis of the electrostatic component of the interaction.
Experimental results were analyzed by using the following
equation (27, 28).
2ln Kd 5 Ao 1 G6 ln @salt# (Eq. 15)
where A° is the value of 2ln Kd where [salt] 5 1 M and G6 is the
phenomenological coefficient expressing the linkage between
the change in ln Kd and the change in ln [salt].
Fig. 5 shows that the plot of the apparent Kd of GpIba1–282
binding to thrombin as a function of salt concentration is linear
with G6 values equal to 24.6 6 0.4 for NaCl and 24.3 6 0.4 for
TMACl.
The extrapolated Kd value of GpIba1–282 binding to thrombin
at 1 M NaCl and TMACl was equal to 2 6 0.2 and 1.6 6 0.2 mM,
FIG. 1. SDS-PAGE Western blot under reducing conditions of
purified glycocalicin (A), purified GpIba1–282 fragment obtained
from mocarhagin treatment of washed platelets (B), and puri-
fied GpIba1–271 fragment obtained from mocarhagin and car-
boxypeptidase Y treatment (C). The Western blots were accom-
plished by using the SZ2 MoAb, recognizing the N-terminal region of
GpIba. D, SDS-PAGE of purified GpIba1–282; E, SDS-PAGE of purified
GpIba1–271. In the middle of the figure, the reference molecular mass
standards are reported: 116 kDa, b-galactosidase (from E. coli); 66 kDa,
bovine serum albumin; 48.5 kDa, fumarase (from porcine heart); 29
kDa, carbonic anidrase (from bovine erythrocytes).
FIG. 2. Solid phase binding experiments dealing with HD22
effect on thrombin interaction with the immobilized GpIba1–282
fragment. The total thrombin concentration is reported, and the bound
thrombin was evaluated at 0 (l ), 50 nM (E), 100 nM (M), 150 (f), and
200 nM () HD22 oligonucleotide. Continuous lines were drawn by
simultaneously fitting all the experimental data to Equations 9–14,
with the following best fit parameter values: Kd 5 24 6 5 nM, and Ki 5
149 6 15 nM, and DAmax 5 6.96 6 0.3 3 10
24 (DA/min405 nm). The
experimental points are the mean from two different measurements,
with the vertical bars representing the standard deviations.
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respectively. These values should give the equilibrium dissoci-
ation constant reflecting the nonionic driving force for GpIba
binding to thrombin, as previously proposed on the basis of a
general thermodynamic analysis (27).
Finally, it is noteworthy that also the anions present in
solution contribute to the electrostatics of thrombin-GpIba1–282
interaction, as at 0.2 M NaF the apparent Kd was 4-fold lower
than that measured at 0.2 M NaCl (0.15 mM and 0.6 mM,
respectively).
Effect of GpIba1–282 and GpIba1–271 Fragments on Thrombin-
AT-Heparin Interaction—GpIba1–282 produced a concentration-
dependent decrease in the heparin-catalyzed rate of thrombin
inhibition by antithrombin (Figs. 6 and 7). In contrast, GpIba1–
271 had no effect on the rate of this interaction (Fig. 6). These
findings, together with the binding data, strongly suggest that
the region encompassing Asp272–Glu282, which is released by
carboxypeptidase Y, contains the thrombin-binding domain.
It is noteworthy that the calculated value of kuncat did not
change as a function of GpIba1–282 concentration, as detailed in
the legend to Fig. 6, implying that the thrombin-AT interaction
per se is unaffected by the fragment. Further support for this
concept comes from the observation that, in the absence of
heparin, the kinetics of the thrombin-AT interaction was unaf-
fected by the GpIba1–282 fragment (kinhib 5 8 3 10
3 M21 s21
versus 7 3 103 M21 s21 in the absence and presence of 1 mM
GpIba1–282 fragment, respectively; data not shown).
By applying Equation 6, we analyzed the effect of the
GpIba1–282 fragment on the kcat/KTzATH value of thrombin in-
teraction with the AT-heparin complex. The kcat/KTzATH value
decreased as a function of the GpIba1–282 concentration, con-
sistent with competitive inhibition of thrombin binding to the
AT-heparin complex by GpIba1–282. Therefore, the inverse of
calculated values of kcat/KTzATH were fitted to Equation 6 and
plotted in Fig. 8. This analysis yielded an apparent Ki value of
188 6 35 nM at 0.15 M NaCl.
Effect of Intact Platelets on the Heparin-catalyzed Inhibition
of Thrombin by Antithrombin III—Paraformaldehyde-treated
platelets attenuate the heparin-catalyzed inhibition of throm-
bin by AT, as shown in Fig. 9. This effect was proportional to
the platelet concentration, over a range of 30,000–200,000/ml.
Depletion of platelet GpIba by mocarhagin treatment almost
completely eliminated such an effect (Fig. 9). Paraformalde-
hyde-treated platelets were used in these experiments to cir-
cumvent the effect of platelet-derived heparin neutralizing pro-
teins such as platelet factor 4 or von Willebrand factor.
Consequently, the inhibiting effect of intact platelets likely
reflects GpIba, which is missing in the mocarhagin-exposed
platelets.
The platelet attenuation of the heparin-catalyzed inhibition
FIG. 3. Solid phase binding experiments pertaining to throm-
bin interaction with immobilized GpIba1–282 fragment in the
absence (l ) and in the presence of 200 nM () HD1 oligonucleo-
tide. The experimental points pertaining to thrombin interaction with
immobilized GpIba1–271 (M) are also reported for comparison. The con-
tinuous line, pertaining to the absence of HD1, was drawn by fitting the
experimental points to a single site binding equation with the following
best fit parameter values: Kd 5 120 6 11 nM and DAmax 5 7.2 6 0.3 3
1024 (DA/min405 nm).
FIG. 4. Solid phase binding experiments pertaining to gT-
thrombin interaction with immobilized GpIba1–282 fragment in
the absence (l ) and in the presence of 1 mM () HD22. The
continuous line was drawn by fitting the experimental points to a single
site binding equation with the following best fit parameter values: Kd 5
281 6 43 nM and DAmax 5 5.1 6 0.3 3 10
24 (DA/min405 nm).
FIG. 5. Salt dependence of the thrombin interaction with the
GpIba1–282 fragment. The experimental details are reported under
“Experimental Procedures.” Observed equilibrium dissociation con-
stants (mean of two determinations) of binding to thrombin, Kd, were
measured as a function of NaCl (l ) and TMACl (E). The linear fits were
drawn according to Equation 15, with the following best fit parameter
values: Kd° 5 26.2 mM and 1.6 6 0.2 mM and slope 5 24.6 6 0.4 and
24.3 6 0.4 for NaCl and TMACl, respectively.
FIG. 6. Time course of thrombin inactivation by AT-heparin in
the absence ( l ) and presence (E) of 400 nM GpIba
1–282
fragment.
Thrombin, AT, and heparin concentrations were equal to 1, 25,
and 4 nM, respectively. Experimental points were fitted to
Equation 4, with the best fit parameter values of kobs 5 1.2 6
0.02 3 1022 s21 and 3.9 6 0.08 3 1023 s21 for the reference and
the GpIba1–282, respectively. Data points (M) pertaining to the
effect of 400 nM GpIba1–271 on thrombin-heparin-AT interac-
tion are also shown.
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of thrombin by AT was demonstrated at low thrombin concen-
tration (0.5 nM), whereas at higher enzyme concentration (5
nM), the rate of thrombin inhibition was only minimally af-
fected (data not shown). This phenomenon might reflect the
fact that at higher thrombin concentrations, platelets are no
longer able to buffer all the thrombin molecules present in
solution, and a predominant enzyme fraction is free in solution.
Effect of Aptamers on Thrombin-induced Platelet Aggrega-
tion—The effect of HD22 and HD1 on thrombin-induced plate-
let aggregation was investigated to evaluate the contribution of
the HBS and FRS domains of thrombin to platelet activation.
Although increasing concentrations of either HD1 or HD22
cause progressive inhibition of thrombin-induced platelet ag-
gregation, there are quantitative differences between the ef-
fects of these aptamers. Platelet aggregation was completely
abolished at saturating HD1 concentrations (Fig. 10). In con-
trast, platelet aggregation was markedly inhibited, but not
abolished, by HD22. The effect of HD22 is similar to that
recently reported for heparin, which also reduced platelet ac-
tivation in response to thrombin (22). Like heparin, HD22
inhibits thrombin binding to GpIba, thereby attenuating
thrombin-induced platelet aggregation. However, this agent
did not abolish aggregation, because it did not prevent throm-
bin interaction with protease activated receptor(s) on the plate-
let membrane.
Effect of HD22 on Thrombin-induced Intraplatelet Calcium
Mobilization—The HD22 effect on the thrombin-induced cal-
cium mobilization in both intact and in GpIb-depleted platelets
was studied to test the hypothesis that a competitive inhibition of
the thrombin-GpIb interaction plays a role in the thrombin-
induced platelet inhibition observed in aggregation experiments.
After mocarhagin treatment, ,10% residual GpIb remained
on the platelet membrane (Fig. 11). As previously reported (22),
mocarhagin-treated platelets resemble platelets of Bernard-
Soulier disease, a congenital deficiency of GpIb, because they
exhibit a delayed response to thrombin stimulation resulting in
a longer lag time for calcium rise, compared with intact plate-
lets. The MoAb SZ2, which binds to GpIb, exerts the same
effect. HD22 has no effect on thrombin-induced calcium mobi-
lization in mocarhagin-exposed platelets. In contrast, HD22
produces a concentration-dependent prolongation of lag time in
control platelets (Fig. 12), an effect similar to that of heparin
(22). These results suggest that by binding to the thrombin
HBS, HD22 inhibits only the GpIb-mediated contribution to
platelet activation.
DISCUSSION
Recently, it was found that the major GpIba fragment, re-
ferred to as glycocalicin, reduces the rate of thrombin inactiva-
tion by AT by competing with heparin for binding to the HBS
on thrombin (8). In the present investigation we tested the
hypothesis that the strongly acidic stretch from Asp272 to
Glu282 of GpIba may act as a “heparin-like” ligand for the
FIG. 7. Experimental values of kobs for heparin-catalyzed (4
nM) thrombin inactivation as a function of AT concentration, in
the absence ( l ) and in the presence of 100 nM (M) and 400 nM (E)
GpIba1–282. The continuous lines were drawn according to Equation 5,
with the following best fit parameter values: l , kcat/KTzATH 5 2.1 6
0.08 3 107 M21 s21, kuncat 5 7.3 3 10
3 M21 s21; M, kcat/KTzATH 5 1.2 6
0.1 3 107 M21 s21, kuncat 5 7.5 3 10
3 M21 s21; E, kcat/KTzATH 5 0.7 6
0.03 3 107 M21 s21), kuncat 5 7.4 3 10
3 M21 s21.
FIG. 8. Dependence of observed values of KTzATH/kcat on GpIba1–
282 concentration, analyzed according to Equation 6 at 0.15 M
NaCl. The continuous line was drawn according to the above equation
with the following best fit parameter values: KTzATH/kcat° 5 0.44 6
0.05 3 1027 M s, Ki 5 188 6 35 nM.
FIG. 9. Effect of paraformaldehyde-treated platelets on the
heparin-catalyzed inhibition of thrombin by AT as a function of
platelet number. The rate of 70 mM S-2238 hydrolysis by thrombin (0.5
nM) was measured in the presence of 0.25 mM AT and 15 nM heparin.
Platelet counts were 0 (*), 30,000/ml (E), 50,000/ml (f), 100,000/ml (M),
and 200,000/ml (). The heparin-catalyzed inhibition of thrombin by AT
was progressively attenuated by increasing platelet counts. GpIb de-
pletion on platelets (200,000/ml) by mocarhagin treatment () abolished
such an effect.
FIG. 10. Effect of HD1 (l ) and HD22 () on thrombin-induced
platelet aggregation. Gel filtered platelets were aggregated by addi-
tion of 1 nM human a-thrombin. Continuous lines were drawn according
to a simple inhibition equation with the best fit IC50 values equal to 15
and 13 nM for HD1 and HD22, respectively.
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thrombin HBS, being thus responsible for the competitive in-
hibition of heparin interaction with thrombin. The data re-
ported in this study show that GpIba1–282 reduces the rate of
the heparin-catalyzed thrombin inhibition by AT. This finding
is in agreement with previous data indicating that the region of
the GpIba molecule involved in thrombin ligation encompasses
a large domain of the glycoprotein spanning from Cys209 to
Asp287 (6, 29–32). This region bears a peculiar stretch of acidic
residues from Asp269 to Asp287 comprising three sulfated
groups linked to Tyr276, Tyr278, and Tyr279 (9, 29–32). In this
study we present evidence suggesting that the Asp272–Glu282
region is an essential part of the thrombin-binding domain.
This result emerged from both solid phase binding experiments
and functional studies that investigated the effect of different
GpIba fragments on the heparin-catalyzed thrombin inhibition
by AT. In particular, the salt dependence of GpIba1–282 binding
to thrombin confirmed the major role played by ionic interac-
tions in the formation of the thrombin-GpIba adduct. These
studies showed an invariance of the G6 value in NaCl and
TMACl. This suggests that the parameter is actually an index
of the electrostatic screening of ions on the surface of the
interacting proteins. It is of interest that the same parameter
value for binding of heparin to thrombin is equal to 24.8 (33).
On the other hand, binding of the hirudin fragment 55–65 to
the fibrinogen recognition site of the enzyme, has G6 values of
21.06 and 21.35 in NaCl and choline chloride, respectively (33,
34). Thus, the present results, together with the previous find-
ings, reasonably exclude an involvement of the fibrinogen rec-
ognition site of thrombin and provides further support for the
concept that the HBS mediates the interaction of thrombin
with GpIba1–282. The relevance of thrombin HBS in GpIba
ligation was previously demonstrated by our group in experi-
ments using thrombin chemically modified with pyridoxal
phosphate at HBS domain (7, 22). These experiments showed
that HBS-modified thrombin exhibited both decreased binding
to GpIba and reduced platelet activating capacity (7, 22). The
HBS domain may act as a polyelectrolyte-like segment that is
able to make multiple salt bridges with the polyanionic seg-
ment Asp272–Glu282 on the GpIba molecule.
Recent thermodynamic data showed the occurrence of heat
capacity change (expression of a hydrophobic effect, equal to 21
kcal/mol) in the thrombin-glycocalicin interaction (8). The cur-
rent results may be reconciled with the above finding by hy-
pothesizing that the numerous salt bridges between the two
proteins occur along with burial of a large number of solvating
water molecules when thrombin binds to GpIba, as this solva-
tion process is characterized by a negative heat capacity change
(35).
The above findings strongly suggest that GpIba1–282, and
particularly the segment from Asp272 to Glu282, binds to the
thrombin HBS. The heparin-binding site resides at the C ter-
minus of the B-chain of thrombin and is mainly formed by a
cluster of cationic residues such as Arg93, Arg97, Arg101, Arg175,
Arg233, Lys236, and Lys240 (36–39).2 Our observation that the
G6 parameter is very similar to that pertaining to thrombin
interaction with heparin raises the possibility that the same
cationic residues in the thrombin molecule mediate both inter-
actions. Recent studies with thrombin variants support this
concept. Two thrombin variants with mutations in the HBS
(Arg93 3 Glu and Lys236 3 Glu) did not bind to GpIba. In
contrast, a thrombin variant with a mutation in the FRS (Arg93
3 Glu) bound GpIb with an affinity similar to that of native
enzyme (40). These results are in agreement with our finding
that gT-thrombin, characterized by a severe modification of
FRS and by a normal HBS (26), can bind to GpIba, although
with an affinity that is about 2-fold lower than that of a-throm-
bin. This may be due to a perturbation in gT-thrombin of the
2 The thrombin residue numbers used in the text correspond to res-
idue numbers in the chymotrypsin numbering system.
FIG. 11. Histogram analysis of GpIb
expression on intact and mocarha-
gin-treated platelets. GpIb (CD42b) ex-
pression on platelets exposed to mocarha-
gin is shown on the left (open curve) and
compared with that on intact platelets
(black curve) on the right. Marker was set
according to the proper isotypic control. In
parentheses, geometric mean values of
CD42b fluorescence distribution are re-
ported. One of three representative exper-
iments is shown.
FIG. 12. Effect of HD22 on a-thrombin-induced calcium in-
crease in intact and mocarhagin-exposed platelets. The lag time
(LT) for calcium increase induced by 1 nM a-thrombin was measured in
intact (l ) and mocarhagin-treated (E) platelets as a function of HD22
concentration. For both platelet preparations, the value obtained at
each HD22 concentration was divided by the respective control value
(LT0) obtained in the presence of buffer alone.
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allosteric linkage between FRS and HBS, recently described for
human a-thrombin (41).
Further support for the concept that GpIba interacts with
the thrombin HBS comes from experiments using HD1 and
HD22. Only HD22, which specifically binds to HBS on throm-
bin (19), displaced thrombin from immobilized GpIba1–282. In
contrast, HD1, which binds to FRS on thrombin (23–25), had no
effect.
Another ligand for thrombin HBS, the kringle prothrombin
fragment 2, has been recently shown to competitively inhibit
the binding of glycocalicin to thrombin (8). Fragment 2 also
bears a peculiar anionic motif, DGDEE (residues 68–72), that
makes electrostatic interactions with some residues of the throm-
bin HBS, such as Arg93, Arg97, Arg101, and Arg175 (42, 43).
A recent study by Dr. Guillin’s group (44) showed that gly-
cocalicin reduces the rate of heparin-catalyzed inhibition of
both thrombin and Factor Xa by AT. These investigators
claimed that this effect arises from glycocalicin interaction
with heparin, rendering less heparin available to activate AT
(44). However, this interpretation is not compatible with our
data, suggesting that the highly acidic GpIba stretch 272–282
must be present for GpIba to compete with heparin for binding
to the HBS on thrombin. It is unlikely that this region is able
to interact with heparin because of its high content of acidic
residues. Moreover, analysis of the GpIba sequence 1–450 did
not show any region bearing a “consensus sequence” (such as
COOH-XXX-R-XXX-RR-XX-RR-XXX-R-NH2) that appears nec-
essary for a specific interaction with heparin (45, 46). Further
support for this comes from the work of other investigators who
have shown that heparin blocks the von Willebrand factor-
GpIba interaction by binding to the heparin-binding site of von
Willebrand factor and not by binding to GpIb (47). It may be
thus hypothesized that the high electrostatic component of
thrombin-GpIba interaction involving the thrombin HBS and
the Asp272–Glu282 region of GpIb may act to correctly orient the
two macromolecules, reducing the free energy necessary for the
molecular recognition.
The platelet aggregation experiments demonstrated that
thrombin binding to GpIb might exert a positive effect on
platelet activation, because HD-22 could attenuate, altough not
abolish, the aggregation by thrombin. The effect of HD22 on
thrombin-induced platelet activation may be explained by its
inhibition of thrombin’s HBS ligation to GpIba, as demon-
strated by binding experiments. Moreover, HD-22 could not
exert its inhibitory activity on platelets depleted of GpIb, as
demonstrated by calcium mobilization experiments. This phe-
nomenon was similarly demonstrated for heparin (22). The
incomplete inhibition of platelet activation observed with
HD-22 and heparin is in agreement with other conditions in
which the thrombin-GpIb interaction is inhibited. In fact, Ber-
nard-Soulier or mocarhagin-treated platelets lacking GpIb
show a reduced but not abolished response to thrombin. On the
contrary, blockage of thrombin FRS by HD-1 could cause a
complete inhibition of platelet activation, because the binding
of the enzyme to protease-activated receptor(s) molecules and,
as a consequence, their hydrolysis was inhibited by the
aptamer. Altogether these results corroborate the hypothesis
that GpIb does not bind to the thrombin FRS.
How GpIb can contribute to platelet activation by thrombin
is not yet clear. One possible mechanism is that thrombin
ligation to GpIb may modulate the expression and/or the hy-
drolysis of protease-activated receptor-1 and protease-acti-
vated receptor-4 molecules on the platelet membrane (19, 48–
51). This hypothesis deserves further study.
The physiological role of GpIba binding to the thrombin HBS
remains to be elucidated. The results obtained in vitro showed
that at thrombin concentrations ,5 nM, the enzyme binding to
the high affinity GpIb site protects it from the heparin-cata-
lyzed inhibition by AT. This phenomenon may represent a
general mechanism by which low thrombin concentrations,
being protected from inactivation, may enhance the availability
of catalytically active thrombin necessary for procoagulant ac-
tivities, such as platelet activation or conversion of fibrinogen
to fibrin. These processes involve the active site and the FRS on
thrombin, domains not involved in GpIb ligation. If this mech-
anism occurs in vivo, then the thrombin-GpIb interaction may
serve to regulate thrombin activity.
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